XIGDUO XR (Dapagliflozin; Metformin Hydrochloride) Patent Expiration, LOE Window & CMS Spending

XIGDUO XR (Dapagliflozin; Metformin Hydrochloride) by AstraZeneca: FDA Orange Book core substance LOE 2031-05-12, 8 AB generics, $0 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAstraZeneca
FDA Application & PathwayN205649 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2031-05-12
Last Listed Patent or Exclusivity Date2031-05-12
Orange Book Patents (*PED Extensions)50 patents (25 *PED)
Active AB-Rated Generic Competitors8
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AstraZeneca across sibling Meru public-data platforms.